Chaga Mushroom: What the Evidence Shows on Antioxidants, Immunity and Kidney Safety

What Is Chaga Mushroom?

Chaga mushroom (Inonotus obliquus) is unlike most fungi you would recognize. Rather than forming a cap, it grows as a hard, charcoal-like mass — called a conk — on the bark of birch trees in cold northern regions: Siberia, Scandinavia, Canada, and parts of the northeastern United States. It has been harvested and used in traditional wellness practices across Russia and Eastern Europe for centuries, most commonly as a tea brewed from the dried, ground conk.

Chaga has attracted serious scientific attention over the past two decades, and it has earned it. Its antioxidant activity is striking in laboratory tests, although laboratory results do not necessarily carry over to people. Its immunomodulatory and anti-inflammatory mechanisms are mechanistically plausible and supported by laboratory evidence. Controlled human safety data on Chaga is lacking, and published case reports describe serious kidney injury, so its cautions deserve more attention than they usually get in wellness marketing.

This review examines what the current evidence actually shows — including where the research is strong, where it is preliminary, and where genuine caution is warranted.

Bioactive Compounds: Why Chaga Is Chemically Distinctive

Chaga's biological effects are attributed to several distinct compound classes that work through different mechanisms:

• Beta-glucan polysaccharides — complex carbohydrates that interact with immune receptors (Dectin-1, TLR-2) to modulate immune cell activity. The same compound class responsible for Reishi and Lion's Mane immune effects, though Chaga's polysaccharide structure differs.
• Betulinic acid — a triterpene derived from the birch bark substrate on which Chaga grows. Has demonstrated anticancer and anti-inflammatory properties in laboratory studies, particularly against melanoma cell lines.
• Melanin complex — Chaga's most distinctive compound and one of the primary drivers of its extraordinary antioxidant capacity. The dark pigment gives Chaga its black exterior and contributes significantly to its free radical scavenging ability.
• Phenolic compounds — including inonoblins and phelligridins, which contribute additional antioxidant activity and have demonstrated anti-inflammatory properties in cell studies.
• Sterols — including lanosterol and ergosterol, which serve as precursors to vitamin D and have structural roles in fungal cell membranes.

This multi-compound profile is why Chaga research spans multiple health applications — different compounds drive different mechanisms.

Antioxidant Activity: The Strongest Evidence

Chaga's antioxidant properties represent its most robustly documented benefit. A laboratory study published in the Journal of Ethnopharmacology tested four Chaga extracts. The polyphenolic extract showed strong antioxidant activity and protected a human skin-cell line from hydrogen peroxide-induced oxidative stress, the extract containing triterpenoids and steroids was relatively strong, and the polysaccharide extract was inactive¹. The study did not compare Chaga with other medicinal mushrooms.

The primary mechanism is the melanin complex — the same pigment that gives Chaga its distinctive black exterior. Melanin is a potent free radical scavenger, and Chaga contains it in concentrations far exceeding most other natural antioxidant sources. The phenolic compounds (inonoblins, phelligridins) provide an additional antioxidant layer through different biochemical pathways.

An important caveat: high antioxidant activity in laboratory assays does not automatically translate to equivalent antioxidant effects in the human body. Bioavailability — how well these compounds are absorbed and utilized after oral consumption — remains incompletely studied for Chaga specifically. This is a gap that applies to many botanical antioxidants and does not negate the evidence, but it does argue for measured expectations about the magnitude of effect.

Immune System Modulation

Preclinical Evidence

Multiple cell culture and animal studies demonstrate that Chaga polysaccharides enhance immune cell function. A study in the International Journal of Biological Macromolecules found that Chaga polysaccharides enhanced macrophage phagocytosis (the ability to engulf and destroy pathogens) and stimulated cytokine production in mice¹⁴ — two fundamental components of effective innate immune response.

Human Evidence

We did not find any published human trial of Chaga on immune function in PubMed. The immune evidence therefore rests on laboratory and animal work: it supports a plausible mechanism, but it cannot show that Chaga strengthens immune defense in people. Larger, well-controlled human trials are needed before any immune benefit can be claimed.

Anti-inflammatory Properties

Inflammation is the underlying driver of most chronic disease, and Chaga's anti-inflammatory mechanisms have been studied across multiple laboratory models. Cell culture studies show that Chaga extracts suppress production of pro-inflammatory cytokines — including TNF-α, IL-6, and IL-1β — and reduce NF-κB signaling, a key inflammation regulatory pathway.

An animal study found that Chaga extract reduced inflammation in colitis-induced mice, suggesting potential applications for inflammatory bowel conditions. While animal-to-human translation is uncertain, this finding aligns mechanistically with the cytokine suppression data from cell studies.

Human clinical trials specifically testing Chaga's anti-inflammatory effects have not yet been conducted. This is a consistent pattern across Chaga research — strong laboratory signals, little or no human data, and a gap where well-designed clinical trials should be.

Anticancer Research: Promising but Preliminary

This is the area where it is most important to be precise about what the evidence does and does not show.

What laboratory research shows: Multiple in vitro studies have demonstrated that various Chaga extracts can inhibit proliferation and induce apoptosis (programmed cell death) in cancer cell lines, including lung, colon, liver, and hepatoma cells. Betulinic acid has shown particular activity against certain melanoma cell lines. A 2008 laboratory study found that a Chaga water extract reduced the viability of human hepatoma (liver cancer) cells, with cell-cycle arrest and apoptosis⁷, and a 2018 study found that a Chaga water extract was more cytotoxic to human lung adenocarcinoma cells than to a bronchial epithelial cell line⁸.

What this does not mean: No human clinical trials have evaluated Chaga as a cancer treatment. The gap between laboratory cell culture findings and clinical efficacy in humans is substantial and well-documented across oncology research — many compounds that kill cancer cells in a dish fail in human trials due to issues of bioavailability, tumor microenvironment, systemic effects, and selectivity. Chaga should never be considered a replacement for evidence-based cancer treatment. Anyone interested in Chaga as an adjunct during cancer care should discuss with their oncologist, because its safety alongside cancer treatments has not been studied, and a published case report describes kidney failure in a patient who took Chaga powder for liver cancer⁹.

Blood Sugar and Metabolic Effects

Limited animal research suggests Chaga may support glucose regulation. In diabetic mice, Chaga polysaccharides improved blood glucose and insulin sensitivity¹⁵, and a Chaga water extract reduced fasting blood glucose¹⁶.

Clinical evidence in humans with diabetes is insufficient to support Chaga as a metabolic management tool. This is an early-stage research area worth watching, but not actionable in clinical practice at this point.

Safety: Important Considerations

Traditional use is not a safety study, and we did not find any controlled human safety trials of Chaga. The medical literature does contain case reports of kidney injury^9,10,11, and there are several other specific risks that are often not adequately disclosed in wellness contexts. These deserve careful attention.

Drug Interactions

• Anticoagulants and antiplatelets — A laboratory study found that an extract of cultured Chaga mycelia reduced platelet aggregation in test tubes and in mice¹². We did not find any human interaction studies, so the effect on bleeding risk is unknown, but anyone taking warfarin, aspirin, clopidogrel or similar medicines should ask their prescriber or pharmacist before adding Chaga.
• Immunosuppressants — Chaga's effects on immune function have mainly been studied in laboratory and animal experiments, and its use alongside medicines that suppress immune function (such as those used in organ transplant recipients or autoimmune disease) has not been studied. As a precaution, check with your doctor or pharmacist first.
• Antidiabetic medications — Animal studies suggest Chaga extracts may lower blood glucose^15,16. Whether this matters in people taking insulin or oral diabetes medicines has not been studied, but an additive effect (low blood sugar) is possible, so ask your prescriber or pharmacist first.

Oxalate Content — A Significant Concern

This is one of the most important and underappreciated safety issues with Chaga. Chaga is rich in oxalate, and the amount varies between products: a case report that measured oxalate in three commercial Chaga powders found 2.8 to 14.2 grams of oxalate per 100 grams of powder, which the authors noted was higher than in typical diets¹⁰. Oxalates bind calcium in the kidney and can contribute to calcium oxalate kidney stone formation in susceptible individuals.

Anyone with a personal or family history of kidney stones, reduced kidney function, or conditions that increase oxalate absorption (such as inflammatory bowel disease or short bowel syndrome) should avoid Chaga supplementation. Published case reports describe a 72-year-old woman who started hemodialysis after taking 4 to 5 teaspoons of Chaga powder a day for about six months⁹, a 49-year-old man who developed end-stage kidney disease after long-term use¹⁰, and a 69-year-old man who developed acute kidney injury after taking 10 to 15 grams of Chaga powder (plus vitamin C) a day for three months, whose kidney function recovered after treatment¹¹. In a 2026 rat study, a high dose of Chaga powder caused oxalate crystal deposits and kidney tubule injury¹³. These reports show that "natural" does not mean safe for everyone, and no safe dose has been established.

Who Should Avoid Chaga

• Anyone with a history of kidney stones or reduced kidney function
• People taking blood thinners, immunosuppressants, or diabetes medications — without physician discussion
• Those with autoimmune conditions (Chaga's effects in autoimmune disease have not been studied, so ask your doctor first)
• People who are pregnant or nursing — insufficient safety data
• Those with mushroom or mold allergies

Quality and Sourcing

As a wild-harvested product, Chaga quality varies significantly between suppliers. Oxalate content also differs between commercial Chaga powders (2.8 to 14.2 grams per 100 grams in one report)¹⁰, so different products are not interchangeable. Standardization of active compounds (particularly beta-glucan content) varies widely across commercial products. When choosing a Chaga-containing supplement, third-party testing and standardized beta-glucan content are meaningful quality indicators.